The cystic fibrosis specialist is moving into other lucrative areas.Vertex Pharmaceuticals (NASDAQ: VRTX) is the leader in cystic fibrosis (CF) treatment -- and it expects to hold that title until at least the late 2030s. There's a lot to love about the company's position and the resulting billions ...

https://www.fool.com/investing/2021/05/04/this-bold-statement-by-the-vertex-ceo-means-a-new/?source=iedfolrf0000001

#fool